Payment overview · 2025
General Payments
$200.76
12 reported records · 7 companies
Healthcare provider profile · identity verified
Ashley Gardner, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · SAGINAW, MI · NPI 1467902825
Verified facts
What the public records show
CMS Open Payments records show Ashley Gardner, NP received $200.76 in general payments during 2025 across 12 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.81 | 23.8% | 3 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $34.03 | 16.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.47 | 16.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.99 | 14.4% | 2 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $22.19 | 11.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.01 | 10.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.26 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $200.76 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.81 | 3 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $34.03 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.47 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.99 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| NUVARING Normalized: nuvaring |
Drug | Organon LLC | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
31 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
72 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 330 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 207 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 201 | 52 |
| Metformin Hcl | Metformin Hcl | 189 | 45 |
| Gabapentin | Gabapentin | 163 | 40 |
| Omeprazole | Omeprazole | 155 | 46 |
| Lisinopril | Lisinopril | 143 | 42 |
| Baclofen | Baclofen | 116 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 33 |
| Ibuprofen | Ibuprofen | 105 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 24 |
| Losartan Potassium | Losartan Potassium | 102 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 91 | 17 |
| Eliquis | Apixaban | 85 | 13 |
| Mounjaro | Tirzepatide | 85 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 84 | 24 |
| Simvastatin | Simvastatin | 82 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 24 |
| Jardiance | Empagliflozin | 80 | 17 |
| Furosemide | Furosemide | 75 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 15 |
| Famotidine | Famotidine | 73 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 15 |
| Potassium Chloride | Potassium Chloride | 71 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 15 |
| Trazodone Hcl | Trazodone Hcl | 67 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 19 |
| Trulicity | Dulaglutide | 64 | 19 |
| Montelukast Sodium | Montelukast Sodium | 63 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 57 | 14 |
| Meloxicam | Meloxicam | 55 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 14 |
| Prednisone | Prednisone | 53 | 30 |
| Pregabalin | Pregabalin | 52 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 50 | suppressed |
| Naproxen | Naproxen | 50 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 44 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 43 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 42 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 13 |
| Linzess | Linaclotide | 39 | 12 |
| Ozempic | Semaglutide | 39 | 12 |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 12 |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 32 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 31 | 27 |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 17 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 15 |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 12 |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $200.76 · 12 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Cologuard Collection Kit, Kerendia, NEXPLANON, NUVARING, REXULTI, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error